Xponance Inc. Buys 20,030 Shares of Bristol-Myers Squibb (NYSE:BMY)

Xponance Inc. lifted its stake in Bristol-Myers Squibb (NYSE:BMY) by 7.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 277,469 shares of the biopharmaceutical company’s stock after acquiring an additional 20,030 shares during the period. Xponance Inc.’s holdings in Bristol-Myers Squibb were worth $14,237,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. Norges Bank purchased a new position in Bristol-Myers Squibb during the 4th quarter worth $1,873,696,000. Moneta Group Investment Advisors LLC grew its stake in Bristol-Myers Squibb by 114,228.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 21,469,785 shares of the biopharmaceutical company’s stock worth $1,544,751,000 after buying an additional 21,451,006 shares during the last quarter. Pacer Advisors Inc. grew its stake in Bristol-Myers Squibb by 48.0% during the 4th quarter. Pacer Advisors Inc. now owns 7,830,948 shares of the biopharmaceutical company’s stock worth $401,806,000 after buying an additional 2,540,360 shares during the last quarter. AustralianSuper Pty Ltd purchased a new position in Bristol-Myers Squibb during the 4th quarter worth $86,965,000. Finally, Cowa LLC grew its stake in Bristol-Myers Squibb by 9,777.8% during the 1st quarter. Cowa LLC now owns 1,657,894 shares of the biopharmaceutical company’s stock worth $1,211,000 after buying an additional 1,641,110 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on BMY. Wells Fargo & Company boosted their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Redburn Atlantic downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price target for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. Finally, StockNews.com downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $61.18.

Bristol-Myers Squibb Stock Performance

NYSE:BMY remained flat at $48.30 during midday trading on Friday. The company had a trading volume of 933,790 shares, compared to its average volume of 15,585,065. The firm has a market cap of $97.89 billion, a price-to-earnings ratio of 12.51, a price-to-earnings-growth ratio of 1.44 and a beta of 0.39. The business’s 50-day simple moving average is $51.25 and its two-hundred day simple moving average is $51.57. Bristol-Myers Squibb has a 52-week low of $47.58 and a 52-week high of $70.93. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.43 and a quick ratio of 1.31.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. The firm had revenue of $11.48 billion during the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. Bristol-Myers Squibb’s revenue was up .6% compared to the same quarter last year. During the same period last year, the business posted $1.82 earnings per share. As a group, sell-side analysts expect that Bristol-Myers Squibb will post 6.63 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 4.97%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 62.18%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.